Drug intelligence / Profile preview

PRO-190

Development stage: Phase 1
Lead developer: Right Brain Bio
Administration: Ophthalmic

Overview

PRO-190 is an investigational ophthalmic solution currently being evaluated in a phase I clinical trial for safety and tolerability. The available information indicates it is administered as an eye drop (ophthalmic route), but the precise mechanism of action, molecular modality, developer, and target disease are not specified in public sources. The study focuses on assessing unexpected adverse events following administration of the drug[2].

Beyond the preview

Go deeper on PRO-190.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-190.

Explore the full profile